“Light Path” – Leveraging Lonza’s Experience with Timelines & Cost Reduction of Bioconjugate Drug Substance Supply

Time: 4:45 pm


• Discover Lonza’s ADC capabilities and learn about future capacity increases at the manufacturing site in Switzerland
• Roll-out of a novel ADC manufacturing offer/concept for customers: BioConjugates LightPath Development
• Fast generation of ADC drug substance to support clinical phase I trials; Utilize Lonza’s bioconjugation experience to reduce customer effort to a minimum and accelerate project timelines